产品名称：**ONO-4059 (analog)**
产品别名：**ONO-4059 (analog)**

生物活性：

Description

ONO-4059 analog is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor. IC50 value: sub-nM range [2] Target: Btk in vitro: ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO-4059 shows a favourable safety profile along with promising efficacy in this difficult-to-treat patient population. [1] in vivo: ONO-4059 has demonstrated anti-tumour activity in several pre-clinical models.[1] ONO-4059 potently and dose-dependently reverse clinical arthritis and prevented bone damage in the CIA model.[2]

Solvent&Solubility

In Vitro:

DMSO : ≥ 29 mg/mL (63.53 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1906 mL	10.9529 mL	21.9058 mL
	5 mM	0.4381 mL	2.1906 mL	4.3812 mL
	10 mM	0.2191 mL	1.0953 mL	2.1906 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

References

[1]. Simon Rule,A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. November 15, 2013; Blood: 122 (21)

[2]. Toshio Yoshizawa, et al. Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA). Washington, DC November 9-14, 2012.

[3]. Yamamoto, et al. Preparation of purinone derivatives as selective Btk inhibitors. From PCT Int. Appl. (2011), WO 2011152351 A1 20111208.